Weight-Loss Agents

Eli Lilly Blows Past Revenue Benchmarks, Again Raises Full-Year Outlook

1 week ago talkbio0Tagged earnings, eli lilly, exophthalmos producing substance, full-year guidance, Mounjaro, pharmaceutical innovation, Q3, revenue growth, Weight-Loss Agents, Zepbound

Eli Lilly; Q2 2025 earnings; Q3 2025 earnings; Mounjaro; Zepbound; weight-loss drugs; revenue growth; EPS; full-year guidance; pharmaceutical innovation

Novo Nordisk Launches Surprise Bid for Metsera, Topping Pfizer Offer; Pfizer Alleges Move May Violate Antitrust Law

1 week ago talkbio0Tagged Acquisition, Antitrust, bidding war, Metsera, Novo Nordisk, Obesity, Pfizer, Twice a day, Unsolicited Adverse Event, Weight-Loss Agents

Novo Nordisk; Metsera; Pfizer; acquisition; bidding war; obesity; antitrust; unsolicited bid; weight-loss drugs

Weight-loss drug stocks drop after Trump pledges major price cuts

2 weeks ago talkbio0Tagged Administration occupational activities, Drops - Drug Form, drug price, eli lilly, Glucagon-Like Peptide 1, Nordisk, Ozempic, Wegovy, Weight-Loss Agents

weight-loss drugs; ozempic; wegovy; novo nordisk; eli lilly; stock drop; drug pricing; trump administration; GLP-1

Skye Bioscience’s Nimacimab Fails Mid-Stage Obesity Trial, Stock Plummets

1 month ago talkbio0Tagged CB1 inhibitor, Clinical Setback, Nimacimab, Obesity Trial, Weight-Loss Agents

nimacimab; CB1 inhibitor; obesity trial; clinical setback; weight loss drug

Roche’s Top Three Ambition in Obesity Not Dependent on a Single Megablockbuster

1 month ago talkbio0Tagged cardiometabolic care, Diagnostics, digital health, Ecosystem, Obesity, Portfolio diversification, Roche (company), Weight-Loss Agents

Roche; obesity strategy; ecosystem approach; pharmaceuticals; diagnostics; digital health; cardiometabolic care; portfolio diversification; weight-loss drugs

FDA Scrutinizes Telehealth Firms Like Hims for GLP-1 Drug Advertising Practices

2 months ago talkbio0Tagged Drug Compounding, Glucagon-Like Peptide 1, Hims, Super Bowl ad, Telemedicine, United States Food and Drug Administration, Weight-Loss Agents

FDA; Hims; telehealth; GLP-1; advertising; weight-loss drugs; compound drugs; Super Bowl ad; misleading claims

Novo Nordisk to Cut 9,000 Jobs Globally as New CEO Targets $1.3B Savings by 2026

2 months ago talkbio0Tagged CEO, competition, Doustdar, eli lilly, Financial cost, Financial savings, layoffs, Nordisk, Ozempic, profit guidance, restructuring, Wegovy, Weight-Loss Agents

Novo Nordisk; layoffs; 9000 jobs; cost savings; CEO Doustdar; restructuring; weight-loss drugs; Wegovy; Ozempic; competition; Eli Lilly; profit guidance